Edition:
United Kingdom

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

21.85USD
20 Jul 2018
Change (% chg)

$-0.30 (-1.35%)
Prev Close
$22.15
Open
$22.15
Day's High
$22.67
Day's Low
$21.50
Volume
120,624
Avg. Vol
187,644
52-wk High
$25.60
52-wk Low
$11.93

Select another date:

Thu, May 3 2018

BRIEF-AMAG Pharmaceuticals Announces Q1 Loss Per Share $1.59

* AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RAISES FULL YEAR FINANCIAL GUIDANCE

BRIEF-AMAG Pharmaceuticals Appoints J. Alan Butcher As Executive Vice President

* AMAG PHARMACEUTICALS APPOINTS J. ALAN BUTCHER AS EXECUTIVE VICE PRESIDENT AND CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:

BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide

* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:

BRIEF-AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal

* AMAG PHARMACEUTICALS - ‍CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION​

BRIEF-AMAG Reports Q4 Earnings Of $0.10 Per Share

* TOTAL GAAP REVENUES FOR Q4 OF 2017 WERE $158.3 MILLION, COMPARED WITH $151.6 MILLION

BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN

BRIEF-AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (SNDA) For Feraheme

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR FERAHEME® (FERUMOXYTOL INJECTION) Source text for Eikon: Further company coverage:

Select another date: